fbpx

Your Breast Cancer Risk

IS MORE THAN YOUR FAMILY HISTORY

Play Video
90% of breast cancer is not hereditary.
 
This is where a new type of genetic test comes in: individualized genetic risk assessment.
 
Predict Your Risk

Determine your personal likelihood of developing breast cancer over the next 5 years & lifetime with a combined clinical & polygenic risk.

  1. Complete the quick online questionnaire, pay for your kit and we will ship it once approved by our third party Telehealth doctor.
  2. Collect your specimen from the comfort of your home and ship it back to our lab for processing.

See what the experts say:

Get the geneType Breast Cancer Risk Assessment Test Kit


Add up to seven additional diseases for a total price of $349!

You will receive a
clear, easy to understand report!

geneType is for adults 30 years or older.

We encourage all customers to take advantage of a complimentary consultation with a genetic counselor when your results are returned.

Get in Touch

Have a question about our geneType Breast Cancer Test or other services? Fill out the form below and our team will be in touch.

Accredited For Compliance With NPAAC Standards And ISO 15189
CLIA Number 99D2023356

Brought to you by

geneType logo

References
1. American Cancer Society. URL: https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/breast-cancer-survival-rates.html 2. van der Groep P et al. Cell Oncol (Dordr) 2011;34:71 -88. 3. Dite GS et al. Cancer Epidemiol Biomarkers Prev 2016;25:359 -65. 4. Allman R, et al. SNPs and breast cancer risk prediction for African American and Hispanic women. Breast Cancer Res Treat. 2015 Dec;154(3):583-9. 5. Spaeth E, et al. Validation of abridged breast cancer risk assessment model for the general population [abstract]. In: Proceedings of the 2021 San Antonio Breast Cancer Symposium; 2021 Dec 7-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2022;82(4 Suppl):Abstract nr P2-10-06.. 6. Medication Use to Reduce Risk of Breast Cancer, United States Preventative Services Task Force. JAMA. 2019; 322(9):857-867 7. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines); Breast Cancer Screening and Diagnosis. Version 1.2021- April 2022. 8. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines); Breast Cancer Risk Reduction. Version 1.2022 – April 2022 9. Use of Endocrine Therapy for Breast Cancer Risk Reduction. Journal of Clinical Oncology 37, no. 33 (November 20, 2019) 3152-3165. 10. Monticciolo D et al. Breast Cancer Screening Recommendations Inclusive of All Women at Average Risk: Update from the ACR and Society of Breast Imaging. J Am Coll Radiol. 2021 Sep;18(9):1280-1288.

Skip to content